Background and aims : Sustained virological response following antiviral interferon-based
INTRODUCTION
Currently, high rates of sustained virological response (SVR) are achieved in patients with chronic hepatitis C treated with direct-acting antivirals (DAAs) (1) (2) (3) .
Viral eradication is associated with a reduced risk of liver complications, including the occurrence of HCC, as reported in a recent meta-analysis: Relative Risk (RR) = 0.24 in all stages of fibrosis ; RR = 0.23 in advanced liver disease (4) . These results were only supported by studies with IFN-based regimens.
Surprisingly, a high rate of tumor recurrence has been recently reported after antiviral treatment of chronic hepatitis C using DAAs in 16 of 58 patients (28%) with apparent complete remission after HCC treatment (5) . Most of these patients had previous surgical resection or radio-frequency ablation and had favorable prognostic factors with an expected low rate of HCC recurrence (<4-5%) (6) . Another study of 59 patients with HCC remission at start of DAA therapy reported a 29% rate of early HCC recurrence within 6 months of therapy (7) . Similar data has not been suggested by pivotal controlled trials performed in the population of patients with cirrhosis, however patients with a history of HCC had been systematically excluded.
This data prompted us to assess the risk of HCC recurrence in three distinct prospective cohorts of the French ANRS (France REcherche Nord&sud Sida-vih Hépatites) agency including HCV-infected patients with or without cirrhosis who received DAA therapy. The current analyses are focused on HCC patients who underwent curative management for their liver tumor based on hepatic resection, percutaneous ablation or liver transplantation before starting DAA therapy. The rates of HCC recurrence were assessed in this population according to antiviral therapy.
PATIENTS AND METHODS
The present work analyzed three distinct prospective cohorts, sponsored and funded by the ANRS (France REcherche Nord&Sud Sida-HIV Hépatites), namely, ANRS CO22 HEPATHER, ANRS CO12 CIRVIR, ANRS CO23 CUPILT. 5 
ANRS CO22 HEPATHER cohort
The ANRS CO22 HEPATHER cohort « Therapeutic options for hepatitis B and C: a French cohort » is a multicentre observational cohort which aims to include 15 000 HCV-and 10 000 HBV-infected patients, to quantify the clinical efficacy and safety of new hepatitis treatments in real-life, and to identify, at the patient level, which treatment will most likely improve overall health (ClinicalTrials.gov, NCT01953458). HCV-positive patients are defined as patients with positive HCV-RNA or positive anti-HCV antibodies. Each patient gave written informed consent before enrollment and the protocol was conducted in accordance with the Declaration of Helsinki and French law for biomedical research and was approved by the "CPP Ile de France 3" Ethics Committee (Paris, France) and the French Regulatory Authority (ANSM). By December 31st, 2015, 14,379 participants with past or active chronic hepatitis C infection had been recruited; among whom 5,458 had begun a Direct Acting Agent (DAA) therapy from entry.We selected all participants with chronic active hepatitis C and a history of treated hepatocellular carcinoma (HCC) prior to inclusion (n=307), and we excluded patients with progressive or active recurrence of HCC upon inclusion (n=40).
ANRS CO12 CIRVIR cohort
The ANRS CO12 CirVir cohort is a multicentre observational cohort which aims to characterize the incidence of complications occurring in biopsy-proven compensated cirrhosis and to identify the associated risk factors using competing risks analysis (8) .
Patients were recruited in 35 French clinical centres between 2006 and 2012. Inclusion criteria were: histologically proven cirrhosis due to HCV or HBV; Child-Pugh A; and no previous hepatic complications (8) . Patients were seen by physicians every 6 months, and the usual clinical and biological data were recorded. Examination by Doppler US was performed every 6 months. When HCC diagnosis was established, treatment was determined using a multidisciplinary approach according to AASLD guidelines for HCC. (6, 9) All events occurring during follow-up, liver-related or not, were recorded based on information obtained from patient medical files from each centre. Likely cause(s) of death were established.
A total of 1,822 cirrhotic patients were included. Among them, 151 were subsequently excluded from analysis after reviewing individual data either due to non-compliance with inclusion criteria (n=142) or consent withdrawal (n=9). Consequently, 1,671 patients among whom 1,354 had HCV-related compensated cirrhosis, were selected for further analysis. On January 5, 2016, after a median follow-up of 58. 6 [36.5-79 .1] months, a first hepatic focal lesion was observed in 409 patients (30.2%) with a 5-year cumulated incidence (CumI) estimated at 32.3%. Following a diagnostic procedure, more than half of these focal liver lesions remained indeterminate or were considered benign (n=214, 52.3%). A definite diagnosis of primary liver cancer (PLC) was established in the remaining 195 patients: HCC (n=189) and intra-hepatic cholangiocarcinoma (n=6). HCC 5-yr CumI was 13.9%.
ANRS CO23 CUPILT cohort
The ANRS C023 "Compassionate use of Protease Inhibitors in viral C Liver Transplantation" (CUPILT) study is a multicentre, cohort study implemented in 24 French and one Belgian liver transplant (LT) centres (ClinicalTrials.gov number NCT01944527). To be enrolled in this cohort, patients must comply with the following associated criteria, which include: (1) having received a liver transplant for an HCV infection, (2) having experienced an HCV recurrence in any stage of fibrosis, (3) having been treated with second-generation DAAs. All patients provided their informed consent before inclusion.
Among the 699 liver transplant recipients enrolled between October 2013 and December 2015, 330 (47%) received LT for HCC. We excluded patients receiving Peg-interferon concurrently with their DAA regimen (n=12) and those presenting with active HCC recurrence at baseline (n=4). Finally, 314 patients were included in the analysis.
RESULTS
The flow charts of the 3 cohorts are depicted in figure 1 and the main patient characteristics are summarized in table 1.
In the ANRS CO22 HEPATHER cohort, our analysis focused on 267 patients with a history of treated hepatocellular carcinoma (HCC) prior to inclusion among whom 189 received DAA from inclusion (DAA group), 78 did not receive DAA (untreated group). Overall, 147 (78%) patients from the DAA group were male versus 57 (73%, P=0.4107) in the untreated group.
In comparison, patients from the DAA group were younger (mean (+/-SD) age of 62 (+/-9) years versus (vs) 66 (+/-10) years, P=0.0047) and prior HCV interferon-based therapy was more frequent (80% vs 69%, P=0.0529). Severe fibrosis or cirrhosis was also more frequent in the DAA group (78% vs 63%, P=0.0148). No other difference was noticed between the two groups in regards to time between HCC discovery and inclusion (Median 1. 
ANRS CO12 CIRVIR cohort
In the ANRS CO12 CIRVIR cohort, 79 HCC patients were considered to be in remission at least 3 months following the implementation of at least one curative procedure. Overall, most of these patients met Milan criteria (Table 2) . Thirteen patients subsequently received a DAAsbased regimen after anti-tumoral treatment. One patient (7.7%) experienced HCC recurrence after 37.1 months while 31 recurrences occurred among the remaining 66 patients (47.0%) who did not received DAAs.
Overall, 31 recurrences occurred in 1789 untreated person-months (at a rate of 1.73/100 person-months) and 1 recurrence was reported in 90 treated person-months (at a rate of 
ANRS CO23 CUPILT cohort
In the ANRS CO23 CUPILT cohort, 314 liver transplant recipients for HCC were treated with DAA. The mean time between LT and the initiation of DAA was 67 ± 60 months. The planned durations of treatment were as follows: 12 weeks, n= 109 (35%); 24 weeks, n=198 (63.7%); 16 weeks, n=3 (1.0%) and 26 weeks, n=1 (0.3%). Among the 248 patients who reached 12 weeks of follow-up, the overall SVR12 rate was 96.8%. A recurrence of HCC was observed in seven patients (2.2%) (mean age 58.0 +/-8.4 years) within mean time after LT of 70 ± 64 months, 7 ± 3 months, 21 ± 14 weeks following the introduction of DAAs and after obtaining viral clearance, respectively. Five of the seven patients (71%) died 58 ± 47 months after LT.
The characteristics of the seven patients are detailed in Table 3 . At inclusion, six of the seven patients (86%) met Milan criteria. Five patients displayed factors predictive of a recurrence based on histological criteria in the native liver. However, microvascular invasion in the native liver was present in two (28%) of the seven patients, and in two others, without vascular invasion a large number of active nodules was observed (patient 2, n=4; patient 5, n=8).
Moreover, we observed that two patients (patients 4 and 7) experienced a first episode of recurrence when they were considered to be in complete remission after LT and before the introduction of DAA.
DISCUSSION
These three prospective multicentre cohorts, dealing with different patient profiles including cirrhotic and non cirrhotic patients and liver transplant recipients, do not support any evidence of an increased risk of HCC recurrence in patients treated with DAA.
The strength of this present work is the large size of patients treated with DAA and that each cohort contributes unique information that gives consistent results.
The HEPATHER, CirVir and CUPILT cohorts are all characterized by prospective rigorous multicenter protocol-driven systematic data collection and analysis of predefined outcomes.
The HEPATHER cohort included a large number of patients treated with DAAs ensuring a high statistical power to identify an increased risk of events during treatment, while the analyses conducted in the CirVir cohort were performed in incidental cases of well-phenotyped HCC occurring during follow-up of patients, thus ensuring the unbiased record of tumors and their evolution after therapeutic management. The CUPILT cohort included only DAA-treated patients after liver transplantation among whom almost half were transplanted for HCC. The expected risk of recurrence following LT range from 8 to 20% within the first 2 years after LT (10) .
Another strength of our work is our focus on patients previously treated for HCC using curative procedures (hepatic resection, percutaneous ablation or liver transplantation) as we excluded patients treated with chemoembolization. Indeed, the recent Spanish study suggesting an high risk of HCC recurrence have included patients with non curative therapies such as chemoembolization, characterized by high early recurrence rates (5) . With an annual rate of recurrence reaching 20% after resection or percutaneous ablation (6) , it is tempting to speculate that incomplete treatment or mistaken initial staging of tumour burden might also introduce interpretation biases in those retrospective studies. This may lead to an erroneous attribution of DAAs being responsible for HCC recurrence. The prospective design of the cohorts allowed us to cautiously select patients according to tumoral response, in particular those who achieved complete remission after the implementation of a curative procedure and before the introduction of DAA.
Moreover, in 2 of these cohorts (HEPATHER and CIRVIR) we compared HCC patients who received DAA to those who did not. In both cohorts there was no evidence of an increased risk of HCC recurrence in treated compared with untreated patients. Similarly, in the CUPILT cohort which included treated patients only, the observed recurrence rate of 2.2% was lower than the expected rate according to previous studies with Interferon regimen.
DAAS are associated with a SVR in more than 90% of patients and SVR is a variable usually associated with a decreased risk of both HCC occurrence and HCC recurrence. What could explain the paradox of an increased risk of HCC? Authors hypothesized that the rapid control of inflammatory state could impact anti-tumoral immune control allowing for tumor clones emergence (5) . The qualitative and quantitative immune alterations which are associated with chronic HCV infection may be restored in a time-dependent fashion (11) but persists an imbalance between different cytokines/chemokines which may decrease the regional immune control of tumoral clones (12, 13) .
Overall, the analyses performed in these prospective cohorts did not underline a specific link between DAA treatments and the risk of HCC recurrence after the implementation of curative procedures including liver transplantation.
In conclusion, we did not find any evidence that DAA treatment increases the risk of recurrence of HCC in DAA-treated patients compared with untreated patients. In another study, we have also observed a decreased risk of HCC over time in cirrhotic or non cirrhotic patients achieving SVR after DAAs (14) .
The prospective follow-up of a large number of patients included in three distinct cohorts of patients reflecting various clinical profiles ensures the quality of our analyses and the confidence in our conclusions. 
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Lay summary
Since an unexpected high rate of hepatocellular carcinoma (HCC) recurrence after direct acting antiviral (DAA) treatment has been suggested in a retrospective study, we analyzed data from three French prospective multicenter ANRS cohorts of > 6,000 DAA treated patients who underwent curative HCC therapies.
We did not observe an increased risk of HCC recurrence after DAA treatment: the rates of recurrence were similar in treated and untreated patients Survival-free of HCC recurrence
